The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CCRIS 862     1-(2-chloroethyl)-1-nitroso- urea

Synonyms: CHEMBL12746, AGN-PC-00JTIM, AG-E-69326, NSC-47547, KST-1B2093, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MP 655


High impact information on MP 655


Chemical compound and disease context of MP 655


Biological context of MP 655


Anatomical context of MP 655


Associations of MP 655 with other chemical compounds


Gene context of MP 655


Analytical, diagnostic and therapeutic context of MP 655


  1. Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyladenine DNA glycosylase. Matijasevic, Z., Boosalis, M., Mackay, W., Samson, L., Ludlum, D.B. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  2. Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Demidem, A., Morvan, D., Papon, J., De Latour, M., Madelmont, J.C. Cancer Res. (2001) [Pubmed]
  3. Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Bodell, W.J., Tokuda, K., Ludlum, D.B. Cancer Res. (1988) [Pubmed]
  4. Differential potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine in chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro. Oredsson, S.M., Tofilon, P.J., Feuerstein, B.G., Deen, D.F., Rosenblum, M.L., Marton, L.J. Cancer Res. (1983) [Pubmed]
  5. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Maze, R., Carney, J.P., Kelley, M.R., Glassner, B.J., Williams, D.A., Samson, L. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  6. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. Panasci, L., Stinson, S.F., Melnychuk, D., Sandor, V., Miller, W.H., Batist, G., Patenaude, F., Bangash, N., Panarello, L., Alaoui-Jamali, M., Sausville, E. J. Clin. Oncol. (2003) [Pubmed]
  7. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Morvan, D., Demidem, A., Papon, J., De Latour, M., Madelmont, J.C. Cancer Res. (2002) [Pubmed]
  8. N-(2-chloroethyl)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA that are more cytotoxic than mutagenic. Inga, A., Chen, F.X., Monti, P., Aprile, A., Campomenosi, P., Menichini, P., Ottaggio, L., Viaggi, S., Abbondandolo, A., Gold, B., Fronza, G. Cancer Res. (1999) [Pubmed]
  9. Aerobic and hypoxic toxicity of a new class of mixed-function drugs associating nitroimidazoles and chloroethylnitrosourea in nitrosourea-sensitive (Mer-) and -resistant (Mer+) human tumor cells. Mulcahy, R.T., Carminati, A., Barascut, J.L., Imbach, J.L. Cancer Res. (1988) [Pubmed]
  10. Repair of haloethylnitrosourea-induced DNA damage in mutant and adapted bacteria. Kacinski, B.M., Rupp, W.D., Ludlum, D.B. Cancer Res. (1985) [Pubmed]
  11. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Vassal, G., Boland, I., Terrier-Lacombe, M.J., Watson, A.J., Margison, G.P., Vénuat, A.M., Morizet, J., Parker, F., Lacroix, C., Lellouch-Tubiana, A., Pierre-Kahn, A., Poullain, M.G., Gouyette, A. Clin. Cancer Res. (1998) [Pubmed]
  12. Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study. Earhart, R.H., Muggia, F.M., Golomb, F.M. Investigational new drugs. (1985) [Pubmed]
  13. Comparison of DNA interstrand cross-linking and strand breakage by 1,3-bis(2-chloroethyl)-1-nitrosourea in polyamine-depleted and control human adenocarcinoma cells. Seidenfeld, J., Barnes, D., Block, A.L., Erickson, L.C. Cancer Res. (1987) [Pubmed]
  14. Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one on the DNA of mouse L1210 cells. Gibson, N.W., Erickson, L.C., Hickman, J.A. Cancer Res. (1984) [Pubmed]
  15. Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Wu, Z.N., Chan, C.L., Eastman, A., Bresnick, E. Cancer Res. (1992) [Pubmed]
  16. Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea. Fukushima, T., Katayama, Y., Watanabe, T., Yoshino, A., Ogino, A., Ohta, T., Komine, C. Clin. Cancer Res. (2005) [Pubmed]
  17. Isolation of two chloroethylnitrosourea-sensitive Chinese hamster cell lines. Hata, H., Numata, M., Tohda, H., Yasui, A., Oikawa, A. Cancer Res. (1991) [Pubmed]
  18. Comparisons between sensitive and resistant human tumor cell lines regarding effects of polyamine depletion on chloroethylnitrosourea efficacy. Seidenfeld, J., Sprague, W.S. Cancer Res. (1990) [Pubmed]
  19. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Zlotogorski, C., Erickson, L.C. Carcinogenesis (1984) [Pubmed]
  20. Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy? Demidem, A., Morvan, D., Madelmont, J.C. Int. J. Cancer (2006) [Pubmed]
  21. Enhancement by O6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes. Cussac, C., Rapp, M., Mounetou, E., Madelmont, J.C., Maurizis, J.C., Godeneche, D., Dupuy, J.M., Sauzieres, J., Baudry, J.P., Veyre, A. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  22. Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Pieper, R.O., Futscher, B.W., Dong, Q., Erickson, L.C. Cancer Res. (1991) [Pubmed]
  23. Sequence-selective depurination, DNA interstrand cross-linking and DNA strand break formation associated with alkylated DNA. Prakash, A.S., Gibson, N.W. Carcinogenesis (1992) [Pubmed]
  24. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Falkson, C.I., Falkson, G., Falkson, H.C. Investigational new drugs. (1994) [Pubmed]
  25. Novel dynamic flow cytoenzymological determination of intracellular esterase inhibition by BCNU and related isocyanates. Dive, C., Workman, P., Watson, J.V. Biochem. Pharmacol. (1987) [Pubmed]
  26. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Harris, L.C., Remack, J.S., Houghton, P.J., Brent, T.P. Cancer Res. (1996) [Pubmed]
  27. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics. Noë, A.J., Malapetsa, A., Panasci, L.C. Cancer Res. (1994) [Pubmed]
  28. Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Boldogh, I., Ramana, C.V., Chen, Z., Biswas, T., Hazra, T.K., Grösch, S., Grombacher, T., Mitra, S., Kaina, B. Cancer Res. (1998) [Pubmed]
  29. Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Chen, Z.P., Malapetsa, A., Marcantonio, D., Mohr, G., Brien, S., Panasci, L.C. Cancer Res. (1996) [Pubmed]
  30. Cross-linking of DNA induced by chloroethylnitrosourea is presented by O6-methylguanine-DNA methyltransferase. Robins, P., Harris, A.L., Goldsmith, I., Lindahl, T. Nucleic Acids Res. (1983) [Pubmed]
  31. Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture. Weinkam, R.J., Deen, D.F. Cancer Res. (1982) [Pubmed]
  32. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Marcantonio, D., Panasci, L.C., Hollingshead, M.G., Alley, M.C., Camalier, R.F., Sausville, E.A., Dykes, D.J., Carter, C.A., Malspeis, L. Cancer Res. (1997) [Pubmed]
  33. Phosphotriester formation by the haloethylnitrosoureas and repair of these lesions by E. coli BS21 extracts. Carter, C.A., Kirk, M.C., Ludlum, D.B. Nucleic Acids Res. (1988) [Pubmed]
  34. Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines. Chen, Z.P., Remack, J., Brent, T.P., Mohr, G., Panasci, L.C. Clin. Cancer Res. (1999) [Pubmed]
  35. Biochemical and cytotoxic properties of the isomeric forms of N,N'-bis[N-2-chloroethyl)-N-nitrosocarbamoyl] cystamine. Farhi, J.J., Bennoun, M., Tapiero, H., Wang, A.L., Tew, K.D. Biochem. Pharmacol. (1984) [Pubmed]
WikiGenes - Universities